Article
A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.
All News
Article
Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.
Article
In medicine, a field where burnout is becoming the norm, there is much promotion of the idea of work-life balance. In reality, the scales between work and life aren’t really balanced. Is the potential for change on the horizon?
Article
A Medicare study shows that young adults with systemic lupus erythematosus (SLE) exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.
Article
Periodontal disease (PD) is more common in rheumatoid arthritis (RA), especially those with anti-citrullinated protein antibodies (ACPAs). RA activity has been linked to the severity of PD and mucosal inflammation.
Article
Etanercept was FDA approved for use in pediatric psoriasis (PsO) in 2016 and ustekinumab was similarly approved in 2020. This comparative analysis looks at the risk of serious infections (SIE) requiring hospitalization in pediatric PSO patients treated with ustekinumab, etanercept, or
Article
Dr. Jack Cush reviews the past week of news on RheumNow.com.
Dr. John Cush
Tweet
Juvenile and Adult-onset Scleroderma Differ
A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.
https://t.co/57OrgaUNqj https://t.co/Y2puN18ux0
Dr. John Cush
Tweet
Downs Syndrome (1/700) & autoimmune mechanisms - Downs has a 4-6 fold higher risk of JIA, type 1 diabetes, autoimmune thyroid disease and coeliac disease. https://t.co/wVUDRCS96I https://t.co/RosPAkRnPA
Dr. John Cush
Tweet
Brazil study of 1,528 kid lupus (cSLE) shows low mortality (4.1%, n=63); 84%F, age 12 yrs w/ time to death=3.2yrs post-Dx. Cause?1) Sepsis (43%), 2) opportunistic infx(11%), & 3) Pulm hemorrhage (9.5%). Predictors: CNS lupus (HR 2.6) & CKD (HR 4.3) https://t.co/mocrJ2b8Mz https://t.co/TdJ7tFYr1r
Dr. John Cush
Tweet
Finnish population study involving 4180 #JIA patients followed for 6+ years (betw mean ages of 8.3 to 14.8 years), finds that 13% of the JIA patients prescribed psychotropic drugs (vs 10% in controls; p<0.001). Antidepressant use most freq, esp in females https://t.co/PcFhGz291J https://t.co/Ss9NzgC8vp
Dr. John Cush
Tweet
2023 NRMP Match: 365 applicants for Rheum; 97.8% (265 of 271 avail) of Adult Rheum fellow positions matched (only 4/127 programs did not fill their match). Pediatric Rheum 27/41 positions (62.8%)were filled (14/32 programs not filling). https://t.co/VECH6rMHBV https://t.co/MC1jhLCQBk
Dr. Rachel Tate
Tweet
@RheumNow's review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI
Dr. John Cush
Tweet
Without head-to-head trials, do we look to metanalyses? 13 trials of TNF inhibitors in JIA pts - Results at 12-14 weeks. While it ADA looks possibly better, that would be an over-interpretation and misuse of trial data that isnt truly comparable https://t.co/k6QcPZZj67 https://t.co/SwwND1VFfT
Dr. John Cush
Tweet
51 Juvenile SLE (j-SLE) studied for neuropsychiatric Dz (j-NPSLE)- 39% presented with jNPSLE. While no clear biomarker/imaging of j-NPSLE identified, they found CSF neopterin (& IFN-α) levels signif higher w/ active j-NPSLE & CNS involvement (p=0.0008) https://t.co/QM8yJGrBJu https://t.co/4hj1eE2JIC
Dr. John Cush
Tweet
Comparison of MIS-C dz in kids and adults>21 (MISC - A). By Dr Susan Shenoi @RWCSmtg #rwcs23 https://t.co/jvsMLARkCA
Dr. John Cush
Tweet
Serious Infection Risk in Pediatric Psoriasis with Ustekinumab, Etanercept, or MTX
This comparative analysis looks at the risk of SIE requiring hospitalization in pediatric PSO patients treated with ustekinumab, etanercept, or MTX prior to 2016.
https://t.co/kR14nrZzCo https://t.co/ccFJcO0eAj
Dr. John Cush
Tweet
The FDA has added a new indication to the oral JAK inhibitor Cibinqo (abrocitinib) - now approved to treat atopic dermatitis in adolescents 12 to under 18 years old. (Approval is based on a phase 3 JADE TEEN trial. https://t.co/DsQj3BfPmZ https://t.co/0bpb2FAwpg
Dr. John Cush
Tweet
Enthesitis-related arthritis compared in kids - 105 ERA (57 axial vs 48 peripheral). Axial ERA pts were older @onset (12 vs. 11yrs), longer Dx delay(10 vs. 5 mos), higher inflammatory markers, more Hip Dz (53% vs 27%), more biologic Rx (67% vs 21%) https://t.co/KTYn1kv3qO https://t.co/eWbvMSBLxm
Dr. John Cush
Tweet
Have you listened to last week's RheumNow podcast?
Dr. Cush answers the question--is there such a thing as dry synovitis?
https://t.co/Um0JhCfRDv https://t.co/rXOGWOEnlr
